Skip to main content
    I

    Insmed Inc (INSM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $122.88
    +1.72 (+1.42%)

    Market Cap: $26.58B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Insmed Inc (INSM) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Insmed (INSM) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, Insmed reported EPS of -$0.46, below the -$0.34 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    28%(11/40)
    Avg Surprise
    -10.21%

    Upcoming Estimates

    Reports Feb 17, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.33
    Range-$1.12 - -$0.02
    25 analysts
    Revenue Consensus
    $604.78M
    Range$530.18M - $664.88M
    23 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.28
    Range-$0.53 - -$0.06
    6 analysts
    EPS Estimate DriftChange to current
    90d ago-$0.22-25.8%
    60d ago-$0.20-40.0%
    30d ago-$0.20-40.0%
    7d ago-$0.23-19.7%
    Current-$0.28
    Revenue Consensus
    $625.63M
    Range$555.00M - $666.18M
    9 analysts

    Next Report

    INSM has an expected report date of Feb 17, 2027.

    INSM Earnings Call

    The latest INSM earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, INSM beat 11, missed 27 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $524.43M, up 268.4% from $142.34M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.46-$0.34-$0.90 - -$0.09-35.29%MissN/A180 up, 3 downOct 29, 2026$524.43M
    Jun 30, 2026-$0.52-$0.69-$1.09 - -$0.05+24.64%BeatN/A163 up, 0 downAug 6, 2026$425.49M
    Mar 31, 2026-$0.76-$1.00-$1.82 - -$0.68+24.00%BeatN/A132 up, 2 downMay 7, 2026$305.96M
    Dec 31, 2025-$1.54-$1.17-$2.01 - -$0.67-31.62%MissN/A138 up, 0 downFeb 19, 2026$263.84M
    Sep 30, 2025-$1.75-$1.37-$1.69 - -$1.23-27.74%MissN/A132 up, 2 downOct 30, 2025$142.34M
    Jun 30, 2025-$1.70-$1.30-$1.46 - -$1.18-30.77%MissN/A133 up, 0 downAug 7, 2025$107.42M
    Mar 31, 2025-$1.42-$1.20-$1.50 - -$1.01-18.33%MissN/A12N/AMay 8, 2025$92.82M
    Dec 31, 2024-$1.32-$1.23-$1.39 - -$1.03-7.32%MissN/A94 up, 3 downFeb 20, 2025$104.44M
    Sep 30, 2024-$1.27-$1.22-$1.55 - -$1.06-4.10%MissN/A150 up, 1 downOct 31, 2024$93.42M
    Jun 30, 2024-$1.94-$1.23-$1.88 - -$0.50-57.72%MissN/A141 up, 0 downAug 8, 2024$90.34M
    Mar 31, 2024-$1.06-$1.20-$1.38 - -$1.11+11.67%BeatN/A152 up, 2 downMay 9, 2024$75.50M
    Dec 31, 2023-$1.28-$1.13-$1.32 - -$0.95-13.27%MissN/A121 up, 0 downFeb 22, 2024$83.69M
    Sep 30, 2023-$1.11-$1.11-$1.28 - -$0.900.00%In lineN/A101 up, 0 downOct 26, 2023$79.07M
    Jun 30, 2023-$1.78-$1.12-$1.24 - -$1.02-58.93%MissN/A111 up, 0 downAug 3, 2023$77.23M
    Mar 31, 2023-$1.17-$1.10-$1.26 - -$0.88-6.36%MissN/A101 up, 1 downMay 4, 2023$65.21M
    Dec 31, 2022-$1.21-$1.04-$1.13 - -$0.87-16.35%MissN/A110 up, 2 downFeb 23, 2023$59.30M
    Sep 30, 2022-$1.09-$0.87-$0.92 - -$0.86-25.29%MissN/A83 up, 0 downOct 27, 2022$67.73M
    Jun 30, 2022-$0.80-$0.89-$0.95 - -$0.84+10.11%BeatN/A70 up, 0 downAug 4, 2022$65.22M
    Mar 31, 2022-$0.80-$0.87-$0.98 - -$0.77+8.05%BeatN/A80 up, 0 downMay 5, 2022$53.11M
    Dec 31, 2021-$0.95-$0.86-$1.00 - -$0.79-10.47%MissN/A70 up, 0 downFeb 17, 2022$56.12M
    Sep 30, 2021-$0.96-$0.78-$0.89 - -$0.73-23.08%MissN/A5N/AOct 28, 2021$46.76M
    Jun 30, 2021-$0.91-$0.88-$0.95 - -$0.70-3.41%MissN/A5N/AAug 5, 2021$45.37M
    Mar 31, 2021-$0.89-$0.96-$1.12 - -$0.76+7.29%BeatN/A5N/AMay 6, 2021$40.21M
    Dec 31, 2020-$1.00-$0.70-$0.79 - -$0.60-42.86%MissN/A6N/AFeb 25, 2021$41.41M
    Sep 30, 2020-$0.63-$0.59-$0.71 - -$0.51-6.78%MissN/A6N/AOct 29, 2020$43.64M
    Jun 30, 2020-$0.64-$0.62-$0.77 - -$0.43-3.23%MissN/A6N/AAug 6, 2020$42.49M
    Mar 31, 2020-$0.74-$0.72-$0.89 - -$0.58-2.78%MissN/A7N/AApr 30, 2020$36.86M
    Dec 31, 2019-$0.59-$0.58-$0.66 - -$0.42-1.72%MissN/A8N/AFeb 25, 2020$45.71M
    Sep 30, 2019-$0.68-$0.67-$0.75 - -$0.62-1.49%MissN/A8N/AOct 30, 2019$38.88M
    Jun 30, 2019-$0.81-$0.86-$0.95 - -$0.56+5.81%BeatN/A9N/AAug 1, 2019$29.97M
    Mar 31, 2019-$0.96-$1.00-$1.17 - -$0.83+4.00%BeatN/A9N/AMay 7, 2019$21.90M
    Dec 31, 2018-$1.19-$1.05-$1.16 - -$0.93-13.33%MissN/A10N/AFeb 22, 2019$9.84M
    Sep 30, 2018-$1.14-$1.06-$1.16 - -$0.97-7.55%MissN/A10N/AOct 30, 2018N/A
    Jun 30, 2018-$1.00-$1.06-$1.38 - -$0.92+5.66%BeatN/A10N/AAug 2, 2018N/A
    Mar 31, 2018-$0.87-$0.96-$1.82 - -$0.26+9.38%BeatN/A9N/AMay 2, 2018N/A
    Dec 31, 2017-$0.85-$0.64-$0.76 - -$0.46-32.81%MissN/A9N/AFeb 23, 2018N/A
    Sep 30, 2017-$0.69-$0.70-$0.74 - -$0.60+1.43%BeatN/A7N/ANov 2, 2017N/A
    Jun 30, 2017-$0.72-$0.63-$0.66 - -$0.61-14.29%MissN/A7N/AAug 3, 2017N/A
    Mar 31, 2017-$0.60-$0.60N/A0.00%In lineN/AN/AN/AMay 3, 2017N/A
    Dec 31, 2016-$1.10-$0.89N/A-23.60%MissN/AN/AN/AFeb 23, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$6.41, after -$5.59 the year before. It was -$2.84 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$6.41N/A
    Dec 31, 2024-$5.59N/A
    Dec 31, 2023-$5.34N/A
    Dec 31, 2022-$3.90N/A
    Dec 31, 2021-$3.71N/A
    Dec 31, 2020-$3.01N/A
    Dec 31, 2019-$3.04N/A
    Dec 31, 2018-$4.20N/A
    Dec 31, 2017-$2.86N/A
    Dec 31, 2016-$2.84N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,500 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,52314
    2026Q2Jun 30, 20268,17921
    2026Q1Mar 31, 202612,11222
    2025Q4Dec 31, 20256,4025
    2025Q3Sep 30, 202510,24723
    2025Q2Jun 30, 20258,54017
    2025Q1Mar 31, 202510,44119
    2024Q4Dec 31, 202411,25519

    2026Q3 Earnings Call

    Opening remarks

    Will Lewis Chair and Chief Executive Officer Good morning. Today's updates are intended to illustrate three overarching ideas. The first is that Insmed has evolved into a diversified biotechnology company that we believe can generate significant revenue and earnings with substantial growth over the next 10 years and beyond. In addition to exceeding $1 billion in total company revenue year to date, I am pleased to announce that BRINSUPRI has already achieved blockbuster status, having generated more than $1 billion in revenue in its first four full quarters of launch. We believe we have only scratched the surface of the potential addressable patients who may benefit from this first-ever approved foundational medicine in bronchiectasis. While we have treated tens of thousands of patients in the first year, there remain hundreds of thousands of patients already diagnosed and waiting, with potentially millions more who may benefit. We have literally only just begun to see the benefit BRINSUPRI will bring to patients, and this has been achieved while continuing to deliver for patients with NTM with ARIKAYCE. As a result of this performance, we are raising our full year 2026 guidance for both products. I am very proud of the work we have done, but there is always more we can improve upon. I continue to believe the growth road ahead for our medicines is very substantial. Looking ahead, we have forecasted our three lead respiratory assets to collectively grow at a compound annual growth rate of more than 20% over the next 10 plus years. In doing so, we expect our three lead respiratory assets to collectively exceed $14 billion in estimated peak sales, with room for potential upside. BRINSUPRI's peak sales estimate of more than $7 billion does not include the COPD and asthma comorbid patient populations, which we estimate number in the low single-digit millions of additional patients. We believe the future impact of BRINSUPRI on these additional patients, who are on max dose treatments for their conditions but are still suffering damage from exacerbations, could be significant. The consequent revenue generation from success in treating these patients could represent potentially as much as, or even more than, the current $7 billion peak sales estimate. In a moment, I will speak to the initiatives we are deploying to tackle this important opportunity. TPIP is also expected to be a massive product, potentially hitting the market by the end of this decade with a peak sales estimate of more than $6 billion from four separate indications. Thus far, TPIP has distinguished itself within the prostanoid class with superior improvement in six-minute walk distance and PVR reduction, among other efficacy measures, as well as better safety and convenience with its clearly differentiated profile.

    Frequently Asked Questions About INSM

    When is Insmed's next earnings date?

    Insmed's next earnings report is expected for Feb 17, 2027.

    Did INSM beat earnings estimates last quarter?

    No. Insmed reported EPS of -$0.46 for the quarter ended Sep 30, 2026, below the -$0.34 estimate by 35.29%.

    What EPS do analysts expect from INSM next quarter?

    The consensus EPS estimate for Insmed for the quarter ending Dec 31, 2026 is -$0.33 from 25 analysts, with estimates from -$1.12 to -$0.02.

    How often does INSM beat earnings estimates?

    Insmed beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -12.80%.